Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Cash & Equivalents: 2015-2024

Historic Cash & Equivalents for Niagen Bioscience (NAGE) over the last 10 years, with Dec 2024 value amounting to $44.7 million.

  • Niagen Bioscience's Cash & Equivalents rose 98.44% to $64.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $64.3 million, marking a year-over-year increase of 98.44%. This contributed to the annual value of $44.7 million for FY2024, which is 63.44% up from last year.
  • According to the latest figures from FY2024, Niagen Bioscience's Cash & Equivalents is $44.7 million, which was up 63.44% from $27.3 million recorded in FY2023.
  • Niagen Bioscience's 5-year Cash & Equivalents high stood at $44.7 million for FY2024, and its period low was $16.7 million during FY2020.
  • Moreover, its 3-year median value for Cash & Equivalents was $27.3 million (2023), whereas its average is $30.8 million.
  • Per our database at Business Quant, Niagen Bioscience's Cash & Equivalents soared by 69.01% in 2021 and then declined by 27.56% in 2022.
  • Yearly analysis of 5 years shows Niagen Bioscience's Cash & Equivalents stood at $16.7 million in 2020, then surged by 69.01% to $28.2 million in 2021, then declined by 27.56% to $20.4 million in 2022, then soared by 33.68% to $27.3 million in 2023, then soared by 63.44% to $44.7 million in 2024.